Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 53 Carcinoma, Non-Small-Cell Lung 50 Carcinoma, Renal Cell 32 Neoplasms 29 Neoplasm Metastasis 24 Colorectal Neoplasms 21 Carcinoma, Hepatocellular 21 Squamous Cell Carcinoma of Head and Neck 18 Stomach Neoplasms 16 Triple Negative Breast Neoplasms 15 Ovarian Neoplasms 14 Small Cell Lung Carcinoma 11 Pancreatic Neoplasms 11 Lung Neoplasms 11 Hodgkin Disease 11 Carcinoma, Transitional Cell 10 Advanced Cancer 9 Sarcoma 8 Recurrence 8 Head and Neck Neoplasms 8 Solid Tumor 7 Prostatic Neoplasms 7 Lymphoma, Non-Hodgkin 7 Endometrial Neoplasms 7 Uterine Cervical Neoplasms 6 Urinary Bladder Neoplasms 6 Carcinoma, Merkel Cell 6 Breast Neoplasms 6 Mesothelioma 5 Glioblastoma 5

Interventions

tocilizumab 1 selicrelumab 1 niraparib 1 durvalumab 1 cobimetinib 1 atezolizumab 1 Tiragolumab 1 Panitumumab 1 PEGPH20 1 Oxaliplatin 1 Optical Imaging 1 Nivolumab 1 Leucovorin 1 Ipilimumab 1 Gemcitabine 1 Fluorouracil 1 Bevacizumab 1 4-fluorobenzoyl-TN-14003 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Pancreatic Adenocarcinoma × Nivolumab × Clear all

NCT03404960 2025-10-10

Parpvax

University of Pennsylvania

Phase 1/2 Completed

104 enrolled 11 charts

Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡